WOOREE BIO Co., Ltd.

WOOREE BIO Co., Ltd.

KKRX:082850
4,260.00
KRW
-5.00
(-0.12%)
-246.08EPS
426.75BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
26,170.71
33,453.25
43,859.25
38,113.45
36,550.28
31,788.75
39,494.32
37,207.73
34,910.53
29,123.21
26,850.5
26,084.18
22,161.82
26,872.3
Basic EPS, GAAP
-274
-751
-718
-999
-309
-817
107
386
750
469
331
100
-199
-176.82
Free Cash Flow per Basic Share
-579.76
-111.33
-1,048.21
-863.69
-185.16
-462.41
974.45
1,176.17
846.98
643.23
328.19
-997.8
263.39
1,793.8
Dividend per Share
50.02
24.98
24.23
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
4,710.37
3,783.8
3,159.5
3,203.66
3,227.38
2,185.26
2,137.86
2,545.28
3,386.89
3,829.41
4,227.12
4,493.61
4,337.25
4,470.85
Tangible Book Value per Share
4,393.76
3,465.58
2,820.72
2,956.98
2,992.52
2,005.85
2,038.87
2,456.54
3,293.55
3,746.48
4,155.85
4,427.68
4,281.84
4,410.39
Basic Weighted Avg Shares
40
39
40
40
40
40
42
44
44
47
47
47
47
38
Sales/Revenue/Turnover
1,039,767
1,305,507
1,764,595
1,533,519
1,474,632
1,279,627
1,672,648
1,623,383
1,543,312
1,355,056
1,263,944
1,237,198
1,043,962
1,014,857
Operating Margin (%)
1.06
0.13
1
-0.56
-0.29
-0.96
1.58
2.41
2.79
2.56
2.12
1.23
0.09
-0.41
Depreciation Expense
39,786
38,353
39,519
35,879
39,564
33,601
40,051
38,845
35,557
36,194
31,850
27,531
27,671
27,503
Net Income, GAAP
-10,886
-29,308
-28,887
-40,195
-12,467
-32,888
4,532
16,841
33,156
21,822
15,581
4,743
-9,374
-6,678
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
41.37
23.58
2.74
21.54
12.81
66.48
- -
- -
Profit Margin (%)
-1.05
-2.24
-1.64
-2.62
-0.85
-2.57
0.27
1.04
2.15
1.61
1.23
0.38
-0.9
-0.66
Working Capital
12,364
-25,852
-165
13,161
-38,232
-51,646
-60,308
11,586
73,542
108,666
135,520
124,407
117,543
117,010
LT Debt
43,028
46,626
56,341
47,533
8,131
22,300
30,743
31,407
34,085
24,503
13,243
55,712
46,981
48,256
Total Equity
282,032
248,464
235,732
233,405
161,916
120,344
127,212
145,125
199,437
226,729
251,103
269,204
261,344
265,902
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
5.69
10.65
13.65
7.93
6.53
1.36
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
3.08
8.03
9.07
6.81
5.21
0.84
- -
- -
Return on Common Equity (%)
-5.8
-17.69
-21.05
-31.42
-9.63
-30.18
5
16.47
24.92
13.07
8.23
2.3
-4.5
-3.18

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
79,918
80,998
85,166
LT Borrowings
39,991
42,353
44,447
LT Finance Leases
5,655
4,628
3,810
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
47
47
47
Market Capitalization
548,786
480,335
426,755

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
589,257
568,796
667,933
Cash, Cash Equivalents & STI
117,829
130,800
161,391
Accounts Receivable, Net
328,216
299,466
354,291
Inventories
85,531
78,809
86,818
Total Current Liabilities
471,586
451,253
550,923
Payables & Accruals
- -
- -
- -
ST Debt
79,918
80,998
85,166
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.86%
13.23%
-2.92%
Free Cash Flow
-87.23%
-125.61%
-126.22%
Net Income, GAAP
-4.13%
-66.62%
-297.64%
Sales/Revenue/Turnover
-4.4%
-8.32%
-15.62%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
292,177
306,675
348,358
289,988
1,237,198
2025
298,303
231,006
263,901
250,752
1,043,962
2026
269,197
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
47
97
75
-592.26
100
2025
-11
-219.27
52.44
-103.49
-199
2026
46.08
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Full Time Employees
95
Sector
Electronic technology
Industry
Electronic production equipment
Address
Ansan-si South Korea
IPO Date
Jul 29, 2005
Business
WOOREE BIO Co., Ltd. (KRX: 082850) is a South Korea-based biotechnology and electronic components manufacturer that develops, produces, and commercializes health functional foods, natural bioactive ingredients, and precision display materials. Founded in May 2000 and headquartered in Ansan-si, Gyeonggi-do, South Korea, the company operates within the Wooree Group alongside affiliates including Wooree Lighting, Wooree E&L, and Wooree Enterprise. The company conducts business across two primary segments: the Bio Division and the Electronics Division. Within its Bio Division, the company provides end-to-end original equipment manufacturing (OEM) and original design manufacturing (ODM) solutions for dietary supplements and nutraceuticals, managing raw material synthesis, formulation development, and finished product packaging under GMP and HACCP certifications; product dosage forms include softgels, hard capsules, tablets, powders, liquids, and stick pouches; proprietary finished consumer health products under brands such as CLARION; and botanical raw materials cultivated in smart vertical plant factories equipped with proprietary LED agricultural lighting systems, supporting commercial extraction of standardized plant compounds and advanced research into medical cannabis and cannabidiol (CBD) formulations. Within its Electronics Division, stemming from its foundational operations as Wooree ETI Co., Ltd. prior to its rebranding in March 2019, the company manufactures flexible printed circuit boards (FPCBs) for mobile devices and flat-panel displays; light-emitting diode (LED) packages and modules; backlight units (BLUs) for liquid-crystal display (LCD) monitors and televisions; and separator components for secondary battery applications. The company distributes its products to commercial clients and consumer markets across South Korea and global export destinations. In recent developments, the company completed a five-to-one share consolidation in September 2026 to optimize its capital structure and enhance trading stability on the KOSDAQ market. In addition, the company expanded its commercial nutraceutical portfolio with the launch of its CLARION brand in late 2025, deploying a line of targeted health supplements, while continuing to advance vertical integration and smart-farm extraction partnerships within the Wooree Group to accelerate the commercialization of high-purity natural functional ingredients and active pharmaceutical materials.